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ABSTRACT
Topoisomerase II is an essential enzyme that is
required for virtually every process that requires
movement of DNA within the nucleus or the opening
of the double helix. This enzyme helps to regulate
DNA under- and overwinding and removes knots
and tangles from the genetic material. In order to
carry out its critical physiological functions, topo-
isomerase II generates transient double-stranded
breaks in DNA. Consequently, while necessary for
cell survival, the enzyme also has the capacity to
fragment the genome. The DNA cleavage/ligation
reaction of topoisomerase II is the target for some
of the most successful anticancer drugs currently in
clinical use. However, this same reaction also is
believed to trigger chromosomal translocations
that are associated with specific types of leukemia.
This article will familiarize the reader with the DNA
cleavage/ligation reaction of topoisomerase II and
other aspects of its catalytic cycle. In addition, it
will discuss the interaction of the enzyme with anti-
cancer drugs and the mechanisms by which these
agents increase levels of topoisomerase II-gener-
ated DNA strand breaks. Finally, it will describe die-
tary and environmental agents that enhance DNA
cleavage mediated by the enzyme.
INTRODUCTION
A number of enzymes that catalyze essential physiological
processes also have the capacity to damage the genome
during the course of their normal activities. For exam-
ple, while the cell requires DNA polymerases to copy
the genetic material, these enzymes insert an incorrect
base approximately every 10
7nt (1). Consequently, in
the absence of mismatch repair pathways, human DNA
polymerases would generate several hundred mutations
every round of cell division. Furthermore, while DNA
glycosylases initiate base-excision repair pathways, these
enzymes can convert innocuous lesions to abasic sites
with far greater mutagenic potential (2). Finally, while
cytochrome P450 enzymes play critical roles in detoxiﬁca-
tion pathways, they sometimes convert inert xenobiotic
chemicals to compounds with mutagenic properties (3).
Of all the enzymes required to sustain cellular growth,
topoisomerase II is one of the most dangerous (4–8).
As discussed below, this enzyme unwinds, unknots and
untangles the genetic material by generating transient
double-stranded breaks in DNA (8–12). Although the
cell cannot survive without topoisomerase II, the strand
breaks that the enzyme generates have the potential to
trigger cell death pathways or chromosomal transloca-
tions (8,13).
This article focuses on the mechanism by which topo-
isomerase II cleaves the genetic material, the ability to
exploit this reaction for the chemotherapeutic treatment
of human cancers and the role of this reaction in triggering
speciﬁc types of leukemia.
DNA TOPOLOGY
The existence of topoisomerases is necessitated by the
structure of the double helix. Each human cell contains
 2m of DNA that are compacted into a nucleus that is
 10mm in diameter (14,15). Because the genetic material
is anchored to the chromosome scaﬀold and the two
strands of the double helix are plectonemically coiled,
accessing the genome is a complex topological challenge
(11,12,16–18).
Topological properties of DNA are those that can
only be changed when the double helix is broken (12).
Two aspects of DNA topology signiﬁcantly aﬀect nuclear
processes. The ﬁrst deals with topological relationships
between the two strands of the double helix. In all living
systems, from bacteria to humans, DNA is globally under-
wound (i.e. negatively supercoiled) by  6% (12,19–21).
This is important because duplex DNA is merely the
storage form for the genetic information. In order to
replicate or express this information, the two strands of
*To whom correspondence should be addressed. Tel: +1 615 322 4338; Fax: +1 615 343 1166; Email: neil.osheroff@vanderbilt.edu
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.DNA must be separated. Since global underwinding of
the genome imparts increased single-stranded character
to the double helix, negative supercoiling greatly facili-
tates strand separation (12,16–18).
While negative supercoiling promotes many nucleic acid
processes, DNA overwinding (i.e. positive supercoiling)
inhibits them. The linear movement of tracking enzymes,
such as helicases and polymerases, compresses the turns
of the double helix into a shorter region (Figure 1)
(12,19–21). Consequently, the double helix becomes
increasingly overwound ahead of tracking systems. The
positive supercoiling that results makes it more diﬃcult
to open the two strands of the double helix and ultimately
blocks essential nucleic acid processes (10,12,16–18).
The second aspect of DNA topology deals with rela-
tionships between separate DNA segments. Intramolecu-
lar knots (formed within the same DNA molecule) are
generated during recombination, and intermolecular
tangles (formed between daughter DNA molecules)
are produced during replication (Figure 1) (8,10,12,17).
DNA knots block essential nucleic acid processes because
they make it impossible to separate the two strands of the
double helix. Moreover, tangled DNA molecules cannot
be segregated during mitosis or meiosis (8,10,12,17).
Consequently, DNA knots and tangles can be lethal to
cells if they are not resolved.
DNA TOPOISOMERASES
The topological state of the genetic material is regulated
by enzymes known as topoisomerases (8,10,11,22,23).
Topoisomerases are required for the survival of all organ-
isms and alter DNA topology by generating transient
breaks in the double helix (8,10,11,22,23). There are two
major classes of topoisomerases, type I and type II, that
are distinguished by the number of DNA strands that they
cleave and the mechanism by which they alter the topolog-
ical properties of the genetic material (8,10,11,22,23).
Eukaryotic type I topoisomerases are monomeric
enzymes that require no high-energy cofactor (11,22,24).
Type I enzymes are organized into two subclasses: type IA
and type IB. These enzymes alter topology by creating
transient single-stranded breaks in the DNA, followed
by passage of the opposite intact strand through the
break (type IA) or by controlled rotation of the helix
around the break (type IB) (11,22,24). Type IA topo-
isomerases need divalent metal ions for DNA scission
and attach covalently to the 50-terminal phosphate of the
DNA (11,22,24). In contrast, type IB enzymes do not
require divalent metal ions and covalently link to the
30-terminal phosphate (11,22,24). As a result of their
reaction mechanism, type I topoisomerases can modulate
DNA under- and overwinding, but cannot remove
knots or tangles from duplex DNA. A number of excel-
lent review articles on type I topoisomerases have
appeared recently (22,24,25). Consequently, these enzymes
will not be discussed further in this article.
Eukaryotic type II topoisomerases function as homo-
dimers and require divalent metal ions and ATP for
complete catalytic activity (5,8,26–28). These enzymes
interconvert diﬀerent topological forms of DNA by a
‘double-stranded DNA passage reaction’ that can be
separated into a number of discrete steps (5,8,26–28).
Brieﬂy, type II topoisomerases (i) bind two separate seg-
ments of DNA, (ii) create a double-stranded break in one
of the segments, (iii) translocate the second DNA seg-
ment through the cleaved nucleic acid ‘gate’, (iv) rejoin
(i.e. ligate) the cleaved DNA, (v) release the translocated
segment through a gate in the protein and (vi) close the
protein gate and regain the ability to start a new round
of catalysis (5,26–34). Because of their double-stranded
DNA passage mechanism, type II topoisomerases can
modulate DNA supercoiling and also can remove DNA
knots and tangles.
TOPOISOMERASE II
Lower eukaryotes and invertebrates encode only a single
type II topoisomerase, topoisomerase II (35–38). In
contrast, vertebrate species encode two closely related
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Figure 1. Nuclear processes induce changes in DNA topology. DNA
replication is used as an example. Although chromosomal DNA is
globally underwound in all cells, the movement of DNA tracking sys-
tems generates positive supercoils. As shown in (A) chromosomal DNA
ends are tethered to membranes or the chromosome scaﬀold (repre-
sented by the red spheres) and are unable to rotate. Therefore, the
linear movement of tracking systems (such as the replication machinery
represented by the yellow bars) through the immobilized double helix
compresses the turns into a shorter segment of the genetic material and
induces acute overwinding (i.e. positive supercoiling) ahead of the fork
(B). In addition, the compensatory underwinding (i.e. negative super-
coiling) behind the replication machinery allows some of the torsional
stress that accumulates in the prereplicated DNA to be translated to
the newly replicated daughter molecules in the form of precatenanes
(C). If these precatenanes are not resolved, they ultimately lead to the
formation of intertwined (i.e. tangled) duplex daughter chromosomes.
Adapted from ref. 10.
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isomerase IIb. These isoforms diﬀer in their protomer
molecular masses (170 versus 180kDa, respectively) and
are encoded by separate genes (8,10,22,28,39–46). Topo-
isomerase IIa and topoisomerase IIb display a high degree
( 70%) of amino acid sequence identity and similar
enzymological characteristics. One notable diﬀerence
between the two isoforms is that topoisomerase IIa relaxes
(i.e. removes) positive superhelical twists  10 times faster
than it does negative in vitro, while the b isoform is unable
to distinguish the geometry of DNA supercoils during
DNA relaxation (47).
Topoisomerase IIa and topoisomerase IIb have distinct
patterns of expression and separate cellular functions.
Topoisomerase IIa is essential for the survival of prolifer-
ating cells, and protein levels rise dramatically during
periods of cell growth (48–51). The enzyme is further
regulated over the cell cycle, with protein concentrations
peaking in G2/M (50,52,53). Topoisomerase IIa is asso-
ciated with replication forks and remains tightly bound
to chromosomes during mitosis (9,51,54–56). Thus, it is
believed to be the isoform that functions in growth-related
processes, such as DNA replication and chromosome
segregation (10,51).
Topoisomerase IIb is dispensable at the cellular level
but appears to be required for proper neural development
(57–59). Expression of topoisomerase IIb is independent
of proliferative status and cell cycle, and the enzyme
dissociates from chromosomes during mitosis (54,60,61).
Topoisomerase IIb cannot compensate for the loss of
topoisomerase IIa in mammalian cells, suggesting that
these two isoforms do not play redundant roles in repli-
cative processes (51,60,62,63). Although the physiological
functions of topoisomerase IIb have yet to be deﬁned,
recent evidence indicates involvement in the transcription
of hormonally or developmentally regulated genes (63,64).
Much of what we understand regarding the mechanism
of action of type II enzymes comes from experiments with
topoisomerase II from species that express only a single
form of the protein. Consequently, eukaryotic type II
topoisomerases will be referred to collectively as topo-
isomerase II, unless the properties being discussed are
speciﬁc to either the a or b isoform.
TOPOISOMERASE II-MEDIATED DNA CLEAVAGE
AND LIGATION
The ability of topoisomerase II to cleave and ligate DNA
is central to all of its catalytic functions (5,8,11,27). All
topoisomerases utilize active site tyrosyl residues to medi-
ate DNA cleavage and ligation. Since type II enzymes
cut both strands of the double helix, each protomer sub-
unit contains one of these residues (Tyr805 and Tyr821
in human topoisomerase IIa and topoisomerase IIb,
respectively).
Topoisomerase II initiates DNA cleavage by the nucleo-
philic attack of the active site tyrosine on the phosphate
of the nucleic acid backbone (Figure 2) (11,23,26,27).
The resulting transesteriﬁcation reaction results in the
formation of a covalent phosphotyrosyl bond that links
the protein to the newly generated 50-terminus of the DNA
chain. It also generates a 30-hydroxyl moiety on the oppo-
site terminus of the cleaved strand. The scissile bonds on
the two strands of the double helix are staggered and are
located across the major groove from one another. Thus,
topoisomerase II generates cleaved DNA molecules with
four-base 50-single-stranded cohesive ends, each of which
is covalently linked to a separate protomer subunit of the
enzyme (65–67).
The covalent enzyme–DNA linkage plays two important
roles in the topoisomerase II reaction mechanism. First, it
conserves the bond energy of the sugar-phosphate DNA
backbone. Second, because it does not allow the cleaved
DNA chain to dissociate from the enzyme, the protein–
DNA linkage maintains the integrity of the genetic mate-
rial during the cleavage event (11,23,26,27). The covalent
topoisomerase II-cleaved DNA reaction intermediate is
referred to as the ‘cleavage complex’ and is critical for
the pharmacological activities of the enzyme, which are
discussed later in this article.
Although topoisomerase II acts globally, it cleaves
DNA at preferred sites (68). The consensus sequence
for cleavage is weak, and many sites of action do not
conform to it (68). Ultimately, the mechanism by which
topoisomerase II selects DNA sites is not apparent, and
it is nearly impossible to predict de novo whether a given
DNA sequence will support scission. Most likely, the spe-
ciﬁcity of topoisomerase II-mediated cleavage is deter-
mined by the local structure, ﬂexibility, or malleability
of the DNA that accompanies the sequence, as opposed
to a direct recognition of the bases that comprise that
sequence (69).
Beyond the nucleophilic attack of the active site tyrosine
on the DNA backbone, the details of topoisomerase II-
mediated DNA cleavage are not well deﬁned. However,
information regarding the roles of speciﬁc amino acid
residues comes from structural studies on the catalytic
core of yeast topoisomerase II generated in the absence
of DNA or in a noncovalent complex with its nucleic
acid substrate (27,70). For consistency, all amino acid
assignments discussed below are for the homologous posi-
tions in human topoisomerase IIa.
Figure 2. Double-stranded DNA cleavage mediated by topoisomerase
II. Scissile bonds are located four bases apart on opposite strands of
the double helix. During cleavage, the active site tyrosine residue of
each topoisomerase II protomer subunit becomes covalently linked to
the newly generated 50-terminal phosphate moiety on each strand. This
covalent linkage preserves the energy of the sugar-phosphate DNA
backbone. The newly generated 30-hydroxyl group interacts with topo-
isomerase II in a noncovalent fashion. Ligation represents the reverse
of this process and leaves the DNA product chemically unchanged
from the initial substrate.
740 Nucleic Acids Research, 2009, Vol. 37, No. 3While not all of the amino acids involved in catal-
ysis have been elucidated, it is believed that the enzyme
utilizes a general acid-base mechanism for DNA cleavage
(Figure 3). Cleavage is initiated when a general base
deprotonates the active site tyrosine hydroxyl, allowing
the oxyanion to attack the scissile phosphate. The base
has not been identiﬁed but is believed to be a conserved
histidine residue.
The DNA cleavage reaction requires a divalent metal
ion (5,30,34,71,72). Mg
2+ appears to fulﬁll this function
in vivo (5). Recent evidence indicates that human topo-
isomerase IIa utilizes a ‘two-metal-ion’ mechanism, in
which one of the metal ions interacts with the bridging
50-oxygen of the scissile bond (34). This interaction greatly
accelerates rates of enzyme-mediated DNA cleavage and
most likely is needed to stabilize the leaving 30-oxygen.
The role of the second metal ion is not known.
However, it is believed to make critical contacts with the
active site tyrosine and may stabilize the DNA transi-
tion state and/or help deprotonate the active site tyro-
sine (34,73). It has been postulated that the divalent
metal ions are coordinated by Glu461, Asp541, Asp543
and Asp545 in human topoisomerase IIa and correspond-
ing residues in the b isoform (Figure 3) (34,70,74,75).
A two-metal-ion mechanism for DNA cleavage mediated
by the bacterial type II topoisomerase, DNA gyrase, also
has been proposed (73).
Topoisomerase II–DNA cleavage complexes normally
are short-lived and readily reversible (5,8,76), and the
DNA cleavage/ligation equilibrium of the enzyme greatly
favors ligation (5,8,11,23,26,27,77,78). Under equilibrium
conditions,  0.5–1% of topoisomerase II in a DNA
scission reaction mixture exists as a cleavage com-
plex (65–67,78,79). Furthermore, when Mg
2+ is utilized
as the divalent metal ion,  1/2–3/4 of the complexes
contain double-stranded breaks with the remainder con-
taining single-stranded DNA breaks. The fact that a
signiﬁcant proportion of cleavage complexes contain
single-stranded breaks was initially taken as an indica-
tion for poor coordination between the two protomer
subunits of topoisomerase II (80). However, with hind-
sight, if the protomers cut the two strands of the double
helix in a completely noncoordinated fashion, virtually
no double-stranded DNA breaks would be generated
(1% 1% 0.01% cleavage complexes). These ﬁndings
suggest that there must be a relatively high degree of coor-
dination between the two protomer active sites of the
enzyme, even if they do not act in complete concert with
one another (78). To this point, once topoisomerase II
cleaves the ﬁrst strand, it is estimated that the enzyme
cuts the second strand  20-fold faster (77,78).
Following strand passage, DNA ligation is initiated
when a general acid extracts the hydrogen from the
30-terminal hydroxyl group. The acid may be a water
molecule or an unidentiﬁed amino acid in the active site
of topoisomerase II. The conversion of the terminal
hydroxyl moiety to an oxyanion induces a nucleophilic
attack on the phosphotyrosyl bond (11,23,26,27). This
action represents the reverse of the cleavage event and
regenerates an intact DNA chain as well as the active
site of topoisomerase II.
It should be noted that the chemical structure of the
ligated DNA is identical to that of the original substrate.
Only the topological properties of the double helix are
altered by the actions of topoisomerase II.
TOPOISOMERASE II AS A CELLULAR TOXIN
Proliferating cells cannot exist without type II topoisome-
rases (5,8,10). However, since these enzymes generate
obligatory double-stranded DNA breaks as part of their
reaction mechanism, they are intrinsically dangerous
proteins. Thus, topoisomerase II assumes a Dr. Jekyll/
Mr. Hyde character; while essential to cell viability, the
enzyme also has the capacity to fragment the genome
(Figure 4). Because of this dual persona, levels of cleavage
complexes are maintained in a critical balance (5,8). When
levels drop below threshold concentrations, daughter
chromosomes remain entangled following replication.
As a result, chromosomes cannot segregate properly
during mitosis and cells die as a result of catastrophic
mitotic failure (Figure 4).
Figure 3. Mechanism of DNA cleavage and ligation mediated by
topoisomerase II. The type II enzyme utilizes a two-metal ion mecha-
nism similar to that utilized by primases and polymerases
(34,70,71,74–77,155,156). Amino acids that are postulated to interact
with the metal ions in the active site of topoisomerase IIa and topoi-
somerase IIb are indicated. One of the metal ions (shown at left) makes
a critical interaction with the 30-bridging atom of the scissile phosphate
(bond shown in red), which most likely is needed to stabilize the leaving
30-oxygen (shown in red). A second metal ion (shown at right) is required
for DNA scission and may stabilize the DNA transition state and/or help
deprotonate the active site tyrosine (Y805 in topoisomerase IIa and Y821
in topoisomerase IIb). Cleavage is initiated when a general base deproto-
nates the active site tyrosine hydroxyl, allowing the oxyanion to attack the
scissile phosphate. The base has not been identiﬁed but is believed to be a
conserved histidine residue. Ligation is initiated when a general acid
extracts the hydrogen from the 30-terminal hydroxyl group. The acid
may be a water molecule or an unidentiﬁed amino acid in the active site
of topoisomerase II. Figure adapted from Noble and Maxwell (73).
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also die, but for diﬀerent reasons (Figure 4). Accumu-
lated topoisomerase II–DNA cleavage intermediates are
converted to permanent strand breaks when replication
forks, transcription complexes or DNA tracking enzymes
such as helicases attempt to traverse the covalently bound
protein ‘roadblock’ in the genetic material (5,8,76,81). The
resulting collision disrupts cleavage complexes and ulti-
mately converts transient topoisomerase II-associated
DNA breaks to permanent double-stranded breaks
that are no longer tethered by proteinaceous bridges
(5,8,76,81). The resulting damage and induction of recom-
bination/repair pathways can trigger mutations, chromo-
somal translocations and other aberrations. When these
permanent DNA breaks are present in suﬃcient numbers,
they can overwhelm the cell and initiate death pathways in
eukaryotes (4,5,7,8,13,76,81).
TOPOISOMERASE II POISONS
Compounds that impact the catalytic activity of topo-
isomerase II can be separated into two categories.
Chemicals in the ﬁrst category decrease the overall activity
of the enzyme and are known as catalytic inhibitors
(5,8,76). Chemicals in the second category increase levels
of topoisomerase II–DNA cleavage complexes. These
latter compounds are said to ‘poison’ the type II enzyme
and convert it to a cellular toxin that initiates the
mutagenic and lethal consequences described above
(5,8,76). Because of their actions, these compounds are
referred to as ‘topoisomerase II poisons’ to distinguish
them from inhibitors that do not aﬀect enzyme-mediated
DNA cleavage/ligation (5,8,76). Although some topo-
isomerase II poisons also inhibit overall activity, the
‘gain of function’ induced by these compounds in the
cell (i.e. increased levels of cleavage complexes) is a domi-
nant phenotype (8,76).
Topoisomerase II poisons increase the concentration of
cleavage complexes by two nonmutually exclusive path-
ways. Some compounds, such as the anticancer drug eto-
poside (see below), act by inhibiting the ability of the
enzyme to ligate cleaved DNA molecules (5,8,76,78).
Other poisons, such as abasic sites and other forms of
DNA damage (see below) work primarily by enhancing
the forward rate of scission (8,76,78). Because of the
manner in which they act, abasic sites poison topoisom-
erase II without inhibiting overall catalytic activity.
Beyond their eﬀects on DNA scission versus ligation,
topoisomerase II poisons (with the exception of DNA
lesions) act by two distinct mechanisms. Compounds in
the ﬁrst group are referred to as traditional, noncovalent,
interfacial or redox-independent topoisomerase II poisons
(8,46,76,82). These chemicals form noncovalent interac-
tions with topoisomerase II at the protein–DNA interface
in the vicinity of the active site tyrosine (8,46,84–87).
Because these compounds also interact with DNA within
the ternary enzyme–DNA–poison complex, they generally
alter the DNA cleavage site speciﬁcity of the enzyme (88).
Finally, their actions against topoisomerase II are not
aﬀected by reducing agents, such as dithiothreitol, and
these compounds induce similar levels of enzyme-mediated
DNA cleavage whether they are added to the binary
topoisomerase II–DNA complex or are incubated with
the enzyme prior to the addition of nucleic acid substrates
(8,82,83,89).
Unlike the traditional poisons, compounds that use the
second mechanism require redox activity to facilitate their
actions against topoisomerase II. The redox-dependent
poisons covalently adduct to the enzyme at amino acid
residues outside of the active site (8,76,89–96) and gener-
ally enhance DNA cleavage at sites that are intrinsically
cut by the enzyme (89,94). Moreover, because these com-
pounds require redox chemistry for activation, their ability
to poison topoisomerase II is abrogated by reducing agents
(89,91,94,97–99). Finally, compounds within this group
enhance DNA cleavage when added to the protein–DNA
complex, but display the distinguishing feature of inhibit-
ing topoisomerase II activity when incubated with the
enzyme prior to the addition of DNA (89,91,94,97–99).
TOPOISOMERASE II AS A TARGET FOR
ANTICANCER DRUGS
Topoisomerase II poisons represent some of the most
important and widely prescribed anticancer drugs cur-
rently in clinical use (Figure 5). These drugs encompass
a diverse group of natural and synthetic compounds that
are commonly used to treat a variety of human
Figure 4. Topoisomerase II is an essential but genotoxic enzyme. The
formation of topoisomerase II–DNA cleavage complexes is required for
the enzyme to perform its critical cellular functions. If the level of
topoisomerase II–DNA cleavage complexes falls too low (left arrow),
cells are not able to untangle daughter chromosomes and ultimately die
of mitotic failure. If the level of cleavage complexes becomes too high
(right arrow) the actions of DNA tracking systems can convert these
transient complexes to permanent double-stranded breaks. The result-
ing DNA breaks, as well as the inhibition of essential DNA processes,
initiate recombination/repair pathways and generate chromosome
translocations and other DNA aberrations. If the strand breaks over-
whelm the cell, they can trigger apoptosis. This is the basis for the
actions of several widely prescribed anticancer drugs. If the concentra-
tion of topoisomerase-mediated DNA strand breaks is too low to over-
whelm the cell, mutations or chromosomal aberrations may be present
in surviving populations. In some cases, exposure to topoisomerase II
poisons has been associated with the formation of speciﬁc types of
leukemia that involve the MLL (mixed lineage leukemia) gene at
chromosome band 11q23 or the chromosome 15;17 translocation that
joins the PML (promyelocytic leukemia) and RARA (retinoic acid
receptor a) genes (lower right arrow).
742 Nucleic Acids Research, 2009, Vol. 37, No. 3malignancies (5,8,76,82,100,101). At the present time, six
topoisomerase II-targeted anticancer agents are approved
for use in the United States, and additional drugs are
prescribed elsewhere in the world (101). These agents all
act as traditional topoisomerase II poisons and function
primarily by inhibiting enzyme-mediated DNA ligation.
One of the ﬁrst topoisomerase II-targeted agents to be
discovered was etoposide, which is derived from podo-
phyllotoxin (100,102). This natural product is found in
Podophyllum peltatum, more commonly known as the
mayapple or mandrake plant (100,102). Podophyllotoxin
has been used as a folk remedy for over a 1000 years
(100,102). The clinical use of this compound as an anti-
neoplastic agent was prevented by high toxicity, but two
synthetic analogs, etoposide and teniposide, displayed
increased antineoplastic activity and decreased toxicity
(100,102). Etoposide was approved for clinical use against
cancer in the mid-1980s and for several years was the most
widely prescribed anticancer drug in the world (100,102).
Etoposide and other drugs such as doxorubicin (and its
derivatives) are front-line therapy for a variety of systemic
cancers and solid tumors, including leukemias, lympho-
mas, sarcomas and breast, lung and germline cancers
(100–102). Mitoxantrone is used to treat breast cancer,
and both it and amsacrine are used to treat relapsed
acute myeloid leukemia (103,104). Every form of cancer
that is considered to be curable by chemotherapy utilizes
treatment regimens that include topoisomerase II-targeted
drugs (100–102,105). In addition to the use of mitoxan-
trone in anticancer regimens, it is used as a treatment for
autoimmune diseases, such as multiple sclerosis (106).
Although topoisomerase II is the cytotoxic target of
the drugs shown in Figure 5, the relative contributions
of topoisomerase IIa and topoisomerase IIb to the chemo-
therapeutic eﬀects of these agents has yet to be resolved.
Some drugs appear to favor one isoform or the other;
however, no truly ‘isoform-speciﬁc’ agents have been
identiﬁed. The issue of isoform speciﬁcity has potential
clinical ramiﬁcations. For example, since topoisomerase
IIa is not expressed appreciably in quiescent cells, the
actions of topoisomerase II-targeted agents against the
b isoform in diﬀerentiated tissues, such as cardiac cells,
most likely are responsible for much of the oﬀ-target
toxicity of these drugs (107–109). Alternatively, since
topoisomerase IIa and topoisomerase IIb are involved in
diﬀerent cellular processes, it may be that cleavage com-
plexes formed with one or the other isoform are more
likely to be converted to permanent DNA strand breaks.
DIETARY TOPOISOMERASE II POISONS
Many foods consumed in the human diet contain natu-
rally occurring topoisomerase II poisons (Figure 6).
Figure 6. Dietary, environmental and DNA-based topoisomerase II
poisons. Abbreviations used are epigallocatechin gallate (EGCG),
N-acetyl-p-benzoquinone imine (NAPQI) and 2-(4-chloro-phenyl)-
[1,4]benzoquinone (40Cl-2,5pQ).
Figure 5. Topoisomerase II anticancer drugs. Structures of selected
topoisomerase II-targeted anticancer drugs are shown.
Nucleic Acids Research,2009, Vol. 37,No. 3 743The most prominent natural products with activity against
the mammalian type II enzymes are the bioﬂavonoids (i.e.
phytoestrogens) (110–113). Bioﬂavonoids represent
a broad group of polyphenolic compounds (including
ﬂavones, ﬂavonols, isoﬂavones and catechins) that are
components of many fruits, vegetables and plant leaves
(114–117). These compounds aﬀect human cells through
a variety of pathways; they are strong antioxidants and
eﬃcient inhibitors of growth factor receptor tyrosine
kinases (114–117). In addition, many bioﬂavonoids, espe-
cially genistein, are potent topoisomerase II poisons
(90,110–113,118–122).
Genistein, which is prominent in soy, is believed to be a
chemopreventative agent in adults that contributes to the
low incidence of breast and colorectal cancers in the Paciﬁc
Rim (Figure 6) (116,117). However, as discussed below,
there also is evidence associating genistein consumption
during pregnancy with the development of infant leuke-
mias (111,123–126). In addition, (–)-epigallocatechin gal-
late (EGCG), the most abundant and biologically active
polyphenol in green tea, is a topoisomerase II poison
(Figure 6) (90,116,121). Many of the therapeutic beneﬁts
of green tea have been attributed to this compound.
The ring structure of genistein is remarkably similar to
that of quinolones (122). These latter compounds, which
target the prokaryotic type II topoisomerases DNA gyrase
and topoisomerase IV, represent the most active and
broad-spectrum antibacterials currently in clinical use
(127–129). Like the quinolones and the anticancer
drugs discussed above, genistein increases levels of topo-
isomerase II–DNA cleavage complexes as a traditional
topoisomerase II poison (122). In contrast, since many
bioﬂavonoids undergo redox chemistry, several members
of the class act as redox-dependent topoisomerase II
points. EGCG and some related catechins poison topo-
isomerase II by this latter mechanism (90,121).
ENVIRONMENTAL TOPOISOMERASE II POISONS
The toxic metabolites of some drugs and industrial
chemicals are topoisomerase II poisons (Figure 6)
(92,93,95,130,131). In all cases described to date, these
chemicals include quinones (aromatic rings that feature
ketone groups) as part of their structures (132–135).
Quinones commonly are produced in the body as a result
of detoxiﬁcation or metabolism pathways (132–135). These
compounds are highly reactive and often damage cells by
generating oxidative radicals and by covalently modifying
proteins and (to a lesser extent) nucleic acids (132–135).
Although acetaminophen is the most widely utilized
analgesic in the world, the second most prevalent cause
of toxic drug admissions to emergency departments
in the United States is overdosage (both accidental
and intentional) of this drug (136). The toxic metabolite
of acetaminophen, N-acetyl p-benzoquinone imine
(NAPQI), is a potent topoisomerase II poison that pro-
duces liver failure (96). Benzene is an industrial solvent
that is associated with the development of human leuke-
mias (130,132–135). One of the most prevalent metabo-
lites of benzene, 1,4-benzoquinone, is a highly reactive
topoisomerase II poison (92,93,95,130,131). Finally,
polychlorinated biphenyls (PCBs), which have multiple
industrial uses, have been linked to a variety of human
health issues (94). The quinone metabolites of these com-
pounds display activity against human type II topoisome-
rases. Consistent with their highly active redox chemistry,
all quinone-based topoisomerase II poisons act in a redox-
dependent manner that involves covalent attachment to
the enzyme (91–93,97).
DNA DAMAGE AS TOPOISOMERASE II POISONS
Several forms of nucleic acid damage enhance topoisomer-
ase II-mediated DNA cleavage (Figure 6) (69,78,137–144).
The type II enzymes are particularly sensitive to abasic
sites, alkylated bases that contain exocyclic rings, and
other lesions that distort the double helix.
DNA damage increases cleavage at naturally occur-
ring sites of topoisomerase II action (69,78,137–144).
In order to enhance cleavage, lesions must be located
within the four-base stagger that separates the two scissile
bonds (69,78,137–144). Unlike the traditional and redox-
dependent topoisomerase II poisons discussed above,
DNA damage has no obvious eﬀect on rates of topoisom-
erase II-mediated ligation and appears to act primarily by
enhancing the forward rate of scission (69,78,137–144).
The physiological beneﬁts of DNA lesions as topoisom-
erase II poisons, if any, are unclear. However, human
topoisomerase IIa and topoisomerase IIb both appear to
play roles in fragmenting genomic DNA and releasing
chromosomal loops during apoptosis (145,146). It has
been suggested that the apoptotic activities of topoisom-
erase II are enhanced (or perhaps triggered) by DNA
lesions that are generated following the release of oxida-
tive radicals from permeable mitochondria in apoptotic
cells (145,146).
TOPOISOMERASE II AND LEUKEMIA
Despite the importance of topoisomerase II in cancer
chemotherapy, evidence suggests that DNA cleavage
mediated by the enzyme can trigger chromosomal translo-
cations that lead to speciﬁc types of leukemia (Figure 4)
(5–8,76,147,148). To this point, 2–3% of patients who
receive regimens that include etoposide or other topo-
isomerase II-targeted drugs eventually develop acute
myeloid leukemias (AMLs). Most of these leukemias
are accompanied by translocations with breakpoints in
the MLL (mixed lineage leukemia) gene at chromo-
somal band 11q23 (6,7,76). The MLL protein is a histone
methyltransferase that regulates the Hox genes, which
control proliferation in hematopoietic cells (6,7,76).
Several breakpoints in MLL have been identiﬁed and
are located in close proximity to topoisomerase II–DNA
cleavage sites (6,7,76).
Recently, a link between topoisomerase II-targeted
drugs and the development of acute promyelocytic
leukemias (APLs) has been observed. Patients with these
leukemias display translocations between the PML (pro-
myelocytic leukemia) gene on chromosome 15 and the
744 Nucleic Acids Research, 2009, Vol. 37, No. 3RARA (retinoic acid receptor a) gene on chromosome 17
(149,150).
In addition to treatment-related leukmias,  80% of
infants with AML or acute lymphoblastic leukemia
(ALL) display translocations that involve the MLL gene
(6,7,111,123–125,147,148,151). The chromosomal translo-
cations associated with these cancers have been observed
in utero, indicating that infant leukemias are initiated
during pregnancy. Epidemiological studies indicate that
the risk of developing these infant leukemias is increased
>3-fold by the maternal consumption of foods that are
high in naturally occurring topoisomerase II poisons such
as genistein or other bioﬂavonoids (111,123–126).
The ability of topoisomerase II poisons to ‘cause’ rather
than ‘cure’ cancer may be related to cellular levels of
topoisomerase II-mediated DNA cleavage complexes. If
the concentration of enzyme-associated DNA breaks is
suﬃcient, DNA recombination/repair pathways can be
overwhelmed and cells will die (5,8,76). However, if the
levels of breaks are not adequate to induce death, path-
ways that promote cell survival can lead to the formation
of stable chromosomal translocations that ultimately lead
to cancerous growth (Figure 4) (5,8,76).
Finally, the speciﬁc contributions of topoisomerase
IIa and topoisomerase IIb to cancer therapy versus leuke-
mogenesis are unclear. However, evidence suggests that
(with at least some drugs) topoisomerase IIa plays a
more important role in cytotoxicity (107,152), while
topoisomerase IIb may play a greater role in triggering
drug-induced cancers (107). Although no isoform-speciﬁc
topoisomerase II-targeted drugs are available at the pres-
ent time, it may be possible to preferentially target topo-
isomerase IIa by scheduling. In this regard, topoisomerase
IIa–DNA cleavage complexes induced by etoposide per-
sist approximately three to four times longer than those
formed with topoisomerase IIb (153,154). Therefore, it has
been suggested that the use of pulsed chemotherapeutic
regimens, in which patients receive cycles of drug treat-
ment followed by recovery, may maintain higher levels
of topoisomerase IIa as compared to topoisomerase IIb
cleavage complexes over the course of therapy (154).
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